LRRK2 Pathway in Parkinson's Disease
Overview
The leucine-rich repeat kinase 2 (LRRK2) pathway represents one of the most significant genetic and molecular contributors to Parkinson's disease (PD). Pathogenic variants in the [LRRK2](/genes/lrrk2) gene are the most common known genetic cause of familial PD, and common polymorphisms at this locus confer substantial risk for sporadic disease. Understanding LRRK2 biology has provided crucial insights into PD pathogenesis and has become a major focus for therapeutic development, with LRRK2 inhibitors now in clinical trials. [@volta2017]
LRRK2 is a large multidomain protein with both kinase and GTPase activity, functioning as a molecular switch that regulates multiple cellular processes relevant to neurodegeneration. The protein is highly expressed in regions affected in PD, including the substantia nigra, and is localized to various cellular compartments where it influences synaptic function, protein clearance, and inflammatory responses. [@alegreabarrategui2019]
LRRK2 Protein Structure
Domain Architecture
LRRK2 is a 2527-amino acid protein with a complex domain structure: [@biskup2006]
Leucine-rich repeats (LRR): Protein-protein interaction domain at the N-terminus
ROC (Ras of complex proteins) domain: GTPase domain that binds and hydrolyzes GTP
COR (C-terminal of ROC) domain: Links ROC to kinase domain, regulates activity
Kinase domain: Catalyzes phosphorylation of substrate proteins
WD40 repeat domain: Mediates protein-protein interactions at C-terminusThis modular architecture allows LRRK2 to function as a scaffolding protein that assembles signaling complexes and as an active enzyme that modifies downstream targets. [@jorgensen2015]
Kinase Domain Structure
The kinase domain of LRRK2 (spanning residues 1879-2138) is a member of the TKL (Tyrosine Kinase-Like) family, distinct from receptor tyrosine kinases. The kinase domain contains: [@mills2022]
- Activation loop: Contains key phosphorylation sites including Ser1292 (a major autophosphorylation site)
- DFG motif: Asp-Phe-Gly motif essential for ATP binding
- A-loop conformation: Kinase activity is regulated by the conformational state of the activation loop
The G2019S mutation lies in the activation loop of the kinase domain, approximately 30 residues C-terminal to the DFG motif. This mutation increases kinase activity approximately 2-fold without altering ATP affinity, making it a gain-of-function mutation that represents the primary therapeutic target for LRRK2 inhibitors. [@kumar2020]
GTPase-Kinase Relationship
LRRK2 possesses an unusual enzymatic architecture where the GTPase and kinase activities are functionally coupled. The ROC domain acts as a molecular switch: [@wallings2019]
- GTP-bound LRRK2 is in an active conformation
- GTP hydrolysis, mediated by ROC intrinsic GTPase activity, returns LRRK2 to an inactive state
- The COR domain coordinates communication between ROC and kinase domains
Pathogenic mutations affect either GTPase activity (affecting ROC domain) or kinase activity (directly increasing phosphorylation), demonstrating that both enzymatic functions are relevant to PD pathogenesis. [@daher2015]
Pathogenic Mutations
Major LRRK2 Mutations
The most common pathogenic [LRRK2](/genes/lrrk2) mutations associated with familial PD include: [@ferreira2017]
| Mutation | Domain | Effect | Frequency | [@tolosa2021]
|----------|--------|--------|-----------| [@steger2017]
| G2019S | Kinase | Increases kinase activity ~2-fold | Most common worldwide | [@pupyshev2021]
| R1441C/G/H | ROC | Impairs GTPase activity | Common in Basque population |
| I2020T | COR | Affects kinase regulation | Found in Japanese families |
| N1437H | ROC | Impairs GTPase activity | Rare |
| Y1699C | COR | Affects domain communication | Rare |
The G2019S mutation (Gly2019→Ser) is the most prevalent, accounting for approximately 5% of familial PD cases and 1-2% of sporadic cases in populations of European ancestry. In certain ethnic groups, such as Ashkenazi Jews and North African Arabs, G2019S accounts for up to 30-40% of PD cases.
Structure-Function Relationships
Different mutations affect distinct enzymatic functions:
- ROC domain mutations (R1441C/G/H): Impair GTP binding/hydrolysis, leading to constitutive kinase activation
- COR domain mutations (I2020T, Y1699C): Disrupt kinase-ROC communication
- Kinase domain mutation (G2019S): Directly increases catalytic activity
Penetrance and Age at Onset
LRRK2-associated PD typically shows incomplete penetrance, with the G2019S mutation having an estimated lifetime risk of developing PD of approximately 30-40% in carriers. The mean age at onset for LRRK2-PD is similar to idiopathic PD (~60 years), though some mutations may be associated with earlier or later onset.
LRRK2 Signaling in Dopaminergic Neurons
Expression in Substantia Nigra
LRRK2 is highly expressed in [dopaminergic neurons](/cell-types/dopaminergic-neurons) of the substantia nigra pars compacta (SNc), the neuronal population most vulnerable in PD. This selective expression pattern explains why LRRK2 mutations primarily cause parkinsonism rather than other neurological disorders.
Regulation of Dopaminergic Neuron Function
In dopaminergic neurons, LRRK2 regulates several critical processes:
a) Dopamine Synthesis and Release
- LRRK2 influences tyrosine hydroxylase (TH) activity, the rate-limiting enzyme in dopamine biosynthesis
- Controls vesicular dopamine storage through regulation of vesicular monoamine transporter 2 (VMAT2)
- Modulates dopamine release at synapses
b) Axonal Maintenance
- LRRK2 phosphorylates Rab proteins involved in axonal transport
- Regulates mitochondrial trafficking along axons
- Controls synaptic vesicle precursor delivery
c) Neuronal Survival
- LRRK2 kinase activity modulates apoptotic pathways
- Regulates autophagy in neuronal processes
- Influences calcium homeostasis
Vulnerability of LRRK2-Mutant Neurons
Dopaminergic neurons carrying pathogenic LRRK2 mutations show enhanced vulnerability to:
- Oxidative stress
- Mitochondrial toxins
- Neuroinflammation
- Protein aggregation
This heightened vulnerability results from the combined effects of impaired cellular clearance pathways, mitochondrial dysfunction, and altered synaptic communication.
Cellular Pathways Regulated by LRRK2
Rab Phosphorylation
A major breakthrough in understanding LRRK2 function was the discovery that LRRK2 phosphorylates a subset of Rab GTPases, key regulators of intracellular membrane trafficking. Key targets include:
- Rab8a: Regulates exocytosis, lysosomal trafficking, and autophagosome formation
- Rab10: Controls endocytic recycling and mitochondrial dynamics
- Rab12: Involved in [autophagy](/entities/autophagy) and lysosomal positioning
- Rab35: Regulates synaptic vesicle trafficking and cytokinesis
Phosphorylation of these Rab proteins at specific threonine residues impairs their ability to interact with effector proteins, disrupting various membrane trafficking pathways relevant to neuronal function and survival.
Synaptic Function
LRRK2 is highly enriched in synaptic terminals where it regulates:
- Synaptic vesicle release and recycling
- Synaptic vesicle protein trafficking
- Dendritic spine morphology
- Neurotransmitter receptor trafficking
Dysregulation of these processes may contribute to the synaptic dysfunction observed in PD.
Protein Clearance Pathways
LRRK2 influences both the autophagy-lysosomal pathway and the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system):
a) Autophagy-Lysosomal Pathway
- LRRK2 kinase activity regulates macroautophagy initiation through phosphorylation of key autophagy proteins
- Mutant LRRK2 impairs lysosomal function by disrupting trafficking of lysosomal enzymes via Rab8a and Rab10 phosphorylation
- LRRK2 phosphorylates components of the autophagy initiation machinery, including proteins involved in phagophore formation
- The autophagy-lysosomal pathway deficit in LRRK2-PD contributes to [alpha-synuclein](/proteins/alpha-synuclein) accumulation
- G2019S knock-in mouse models show age-dependent impairment of autophagic flux
b) Ubiquitin-Proteasome System
- LRRK2 can phosphorylate proteins involved in protein quality control
- Pathogenic mutations may impair recognition of ubiquitinated substrates
- Proteasomal function may be indirectly affected by Rab-mediated trafficking disruptions
- The combined impairment of both degradation pathways creates a synergistic accumulation of damaged proteins
c) Relationship to Parkinson's Disease
- Protein aggregation is a hallmark of PD neuropathology
- Impaired protein clearance pathways contribute to Lewy body formation
- The convergence of LRRK2 dysfunction with other genetic risk factors (GBA, SNCA) accelerates aggregation
Mitochondrial Function
LRRK2 is localized to mitochondria in [neurons](/entities/neurons), where it may influence:
a) Mitochondrial Dynamics
- LRRK2 phosphorylates proteins involved in mitochondrial fusion and fission
- Rab10 phosphorylation affects mitochondrial morphology regulation
- Mutant LRRK2 alters the balance between mitochondrial fission and fusion
- This contributes to the accumulation of dysfunctional mitochondria
b) Mitochondrial Trafficking
- LRRK2 regulates mitochondrial transport along axons through Rab phosphorylation
- Impaired mitochondrial trafficking leads to energy deficits at synaptic terminals
- Synaptic mitochondria are particularly vulnerable in LRRK2-PD
c) Mitophagy
- LRRK2 kinase activity modulates the PINK1-Parkin mitophagy pathway
- Pathogenic LRRK2 mutations impair recognition and clearance of damaged mitochondria
- This creates a positive feedback loop where damaged mitochondria accumulate and produce more ROS
- Mitophagy deficits compound with other mitochondrial abnormalities in dopaminergic neurons
d) Bioenergetic Consequences
- Combined defects in dynamics, trafficking, and mitophagy lead to ATP deficits
- Dopaminergic neurons have high energy demands, making them particularly vulnerable
- Mitochondrial dysfunction contributes to the selective vulnerability of [substantia nigra](/brain-regions/substantia-nigra) neurons
Pathogenic LRRK2 mutations may exacerbate mitochondrial dysfunction, which is already implicated in PD pathogenesis through other genetic risk factors.
LRRK2-GBA Interaction Pathway
Genetic Convergence
The [LRRK2](/genes/lrrk2) and [GBA](/genes/gba) genes represent the two most significant genetic risk factors for Parkinson's disease, and emerging evidence demonstrates they converge on common cellular pathways. GBA mutations (carrying heterozygosity for glucocerebrosidase loss-of-function) increase PD risk by 5-7 fold, while LRRK2 mutations (particularly G2019S) account for 5% of familial PD. Patients carrying both LRRK2 and GBA mutations show earlier onset and more severe phenotypes, suggesting additive or synergistic effects[@gba2024].
Molecular Mechanisms of Convergence
a) Lysosomal Function
Both LRRK2 and GBA converge on lysosomal homeostasis:
- LRRK2 kinase hyperactivity impairs lysosomal enzyme trafficking through Rab phosphorylation
- GBA mutations reduce glucocerebrosidase activity, leading to glycolipid accumulation
- This creates a "double hit" to lysosomal function, compounding protein clearance deficits
- The combination accelerates [alpha-synuclein](/proteins/alpha-synuclein) aggregation through impaired autophagic clearance
b) Autophagy-Lysosome PathwayThe autophagy-lysosome pathway is a key convergence point:
- LRRK2 phosphorylates Rab proteins (Rab8a, Rab10, Rab12) that regulate autophagosome formation and lysosomal trafficking
- GBA deficiency impairs lysosomal function, reducing the final degradative step in autophagy
- Combined impairment creates a bottleneck at the lysosomal degradation stage
- This results in accumulation of damaged proteins and organelles
c) Lipid MetabolismBoth genes influence cellular lipid handling:
- GBA mutations cause glucosylceramide accumulation, altering membrane composition
- LRRK2 activity affects lipid raft function and membrane trafficking
- Lipid dysregulation impacts alpha-synuclein aggregation kinetics
- The lysosomal lipid environment affects alpha-synuclein degradation
Clinical Implications
The LRRK2-GBA interaction has important clinical implications:
- Phenotype: LRRK2-GBA double carriers show earlier age at onset (52-58 years vs. 60-65 years for either alone)
- Progression: Faster motor progression and more severe cognitive impairment
- Treatment response: May influence response to LRRK2 inhibitors and GBA-targeted therapies
- Biomarkers: Combined biomarker signatures may differ from single-gene carriers
Therapeutic Implications
Understanding LRRK2-GBA convergence informs combination therapeutic strategies:
- LRRK2 inhibitors may partially compensate for GBA-related lysosomal deficits
- GBA-enhancing therapies (ambroxol, gene therapy) may benefit LRRK2-PD patients
- Combined targeting may provide additive benefits
- Clinical trials increasingly stratify patients by dual-carrier status
LRRK2 Signaling Cascade Diagram
Mermaid diagram (expand to render)
This diagram illustrates the cascade from LRRK2 kinase hyperactivity through Rab phosphorylation to downstream cellular dysfunctions that contribute to PD pathogenesis, including the convergence with GBA-related lysosomal deficits.
LRRK2 in Neuroinflammation
Microglial Activation
LRRK2 is highly expressed in [microglia](/cell-types/microglia-neuroinflammation), the resident immune cells of the brain, where it regulates inflammatory responses. LRRK2 expression is upregulated in activated microglia, and:
- LRRK2 kinase activity modulates cytokine production
- LRRK2 variants influence microglial inflammatory responses
- LRRK2 may contribute to chronic neuroinflammation in PD
Peripheral Immunity
LRRK2 is also expressed in peripheral immune cells, including T cells, B cells, and monocytes. Genetic variants at the [LRRK2](/genes/lrrk2) locus may influence immune cell function, potentially affecting systemic inflammatory states that impact brain health.
LRRK2 Inhibitors in Development
First-Generation Inhibitors
Early LRRK2 inhibitors included:
- H-1152: Early tool compound with limited CNS penetration
- GSK2578215A: Used extensively in preclinical studies
- LRRK2-IN-1: First widely used chemical probe
Second-Generation CNS-Penetrant Inhibitors
a) DNL151 (Lunastronib) - Denali Therapeutics
- Highly selective LRRK2 inhibitor
- Demonstrated CNS penetration in preclinical models
- Completed Phase 1 studies showing dose-dependent Rab10 phosphorylation inhibition
- Advanced to Phase 2 clinical trials for PD
b) BIIB122 (formerly DNL151) - Biogen/Denali
- Collaboration between Biogen and Denali
- In Phase 2 development for early PD
- Targets LRRK2 kinase activity to potentially slow disease progression
c) DNL312 - Denali Therapeutics
- Next-generation LRRK2 inhibitor
- Improved brain penetration and target engagement
- Currently in preclinical/early clinical development
d) PF-06447475 - Pfizer
- CNS-penetrant LRRK2 inhibitor
- Showed neuroprotection in animal models
- Demonstrated ability to reduce LRRK2 kinase activity in vivo
Mechanism of Action
LRRK2 inhibitors work by:
- Binding to the ATP-binding pocket of the kinase domain
- Reducing autophosphorylation at Ser1292
- Decreasing phosphorylation of Rab substrates
- Restoring normal membrane trafficking in cellular models
Clinical Development Challenges
- Target engagement: Demonstrating sufficient CNS target engagement
- Biomarker validation: Using phospho-Rab10 as pharmacodynamic marker
- Peripheral effects: Managing potential lung and kidney toxicity
- Therapeutic window: Balancing efficacy with safety
LRRK2 Animal Models
Mouse Models
a) Knockout Models
- LRRK2 global knockout mice are viable and fertile
- Show subtle phenotypes including altered dopamine signaling
- Provide insight into LRRK2 normal physiology
b) Transgenic Models
- LRRK2 G2019S knock-in mice: Recapitulate kinase hyperactivity
- LRRK2 R1441G mice: Model ROC domain mutations
- BAC transgenic mice: Express wild-type or mutant human LRRK2
c) Phenotypic Findings
- Age-dependent motor deficits in some models
- Altered dopaminergic neuron function
- Impaired autophagy and lysosomal function
- Mild neuroinflammation
Lower Organism Models
a) Drosophila melanogaster
- LRRK2 knockout or mutant flies show:
- Reduced lifespan
- Locomotor deficits
- Dopaminergic neuron loss
- Mitochondrial abnormalities
- Rapid and cost-effective for screening
b) Caenorhabditis elegans
- Orthologous genes (lrk-1) studied in worm models
- Useful for developmental studies
- Simpler nervous system for mechanistic studies
c) Zebrafish
- LRRK2 knockdown affects dopaminergic neuron development
- Useful for developmental studies
iPSC Models
Human [iPSC-derived dopaminergic neurons](/cell-types/ipsc-derived-dopaminergic-neurons-lrrk2-g2019s) from LRRK2 mutation carriers:
- Recapitulate disease-relevant phenotypes
- Show increased kinase activity
- Exhibit mitochondrial dysfunction
- Useful for drug screening
Clinical Trials Targeting LRRK2
Current Clinical Trials
a) LRRK2 Inhibitor Trials
| Compound | Company | Phase | Status |
|----------|---------|-------|--------|
| BIIB122 | Biogen/Denali | Phase 2 | Recruiting |
| DNL151 | Denali | Phase 2 | Completed Phase 1 |
b) Trial Design Considerations
- Enrollment of LRRK2 mutation carriers vs. sporadic PD
- Biomarker-driven patient selection
- Disease modification endpoints
- Long-term safety monitoring
Outcome Measures
- Clinical: MDS-UPDRS, MoCA, PDQ-39
- Biomarker: Phospho-Rab10 in blood, pSer1292 LRRK2 in CSF
- Imaging: DaTscan, MRI
Challenges in Clinical Development
- Penetrance: Not all carriers develop PD, complicating enrollment
- Age: Most trials enroll older patients; earlier intervention may be more effective
- Biomarkers: Need validated biomarkers for target engagement
- Compensation: Potential for compensatory upregulation with chronic inhibition
Biomarker Development
LRRK2 Activity Biomarkers
Developing biomarkers to track LRRK2 activity in living patients is essential for clinical trials:
- Phospho-Rab10 in peripheral blood mononuclear cells as a pharmacodynamic marker
- pSer1292 LRRK2 in cerebrospinal fluid
- Neuroimaging to assess target engagement
Genetic Testing
Genetic testing for [LRRK2](/genes/lrrk2) mutations is available and may be appropriate for:
- Individuals with early-onset PD and family history
- Populations with high mutation carrier frequency
- Clinical trial enrollment
LRRK2 Kinase Activity Regulation
Autophosphorylation and Activation
LRRK2 kinase activity is dynamically regulated through multiple mechanisms. Autophosphorylation at Ser1292 serves as a major read-out of LRRK2 catalytic activity in vivo. Unlike many kinases where autophosphorylation is constitutive, LRRK2 autophosphorylation levels correlate with the protein's conformational state and are influenced by:
- Protein-protein interactions: Scaffold proteins that bring LRRK2 into proximity with specific substrates
- Subcellular localization: Membrane-associated LRRK2 shows higher activity
- Post-translational modifications: Phosphorylation at other sites modulates kinase function
- Pathogenic mutations: G2019S and other mutations increase autophosphorylation at Ser1292
The kinase domain adopts different conformational states:
- Active conformation: DFG-in, A-loop phosphorylated - high catalytic activity
- Intermediate states: Partial activation with intermediate phosphorylation
- Inactive conformation: DFG-out, A-loop dephosphorylated - minimal activity
Regulation by GTPase Domain
The unique architecture of LRRK2 links GTPase and kinase activities through the COR domain. The ROC GTPase domain functions as a molecular switch:
GTP-bound state: LRRK2 is in an active conformation with high kinase activity
GTP hydrolysis: ROC domain hydrolyzes GTP to GDP, triggering conformational change
GDP-bound state: LRRK2 transitions to a less active conformation
GTP exchange: GDP/GTP exchange reactivates LRRK2This coupling means that pathogenic mutations in either the ROC domain (which impair GTP hydrolysis, maintaining the GTP-bound active state) or the kinase domain (which directly increase catalytic activity) both result in LRRK2 hyperactivity.
Regulatory Kinases
Several kinases can modulate LRRK2 activity:
- CK2 (Casein Kinase 2): Phosphorylates LRRK2 at multiple sites
- PKA (Protein Kinase A): Can modulate LRRK2 membrane association
- PKC (Protein Kinase C): Regulates LRRK2 autophosphorylation
- Rho-associated kinases (ROCK): Influence LRRK2 cytoskeletal localization
Inhibitory Mechanisms
Endogenous inhibitors of LRRK2 include:
- 14-3-3 proteins: Bind to phosphorylated LRRK2 and regulate its activity
- Heat shock proteins: Hsp90 and other chaperones regulate LRRK2 folding and stability
- Protein phosphatases: PP1 and PP2A can dephosphorylate LRRK2
Autophagy and Lysosomal Dysfunction
LRRK2 Regulation of Autophagy
LRRK2 plays a complex role in regulating the autophagy-lysosome pathway, with both positive and negative regulatory effects depending on context and cellular state.
Initiation
LRRK2 kinase activity influences the initiation of autophagy:
- Phosphorylation of Rab proteins affects the localization of autophagy initiation complexes
- LRRK2 can modulate mTORC1 activity, a key regulator of autophagy initiation
- Rab8a and Rab10 phosphorylation affects omegasome formation
Maturation and Flux
LRRK2 regulates autophagosome-lysosome fusion:
- Rab8a phosphorylation impacts SNARE complex assembly
- LRRK2 affects lysosomal positioning and distribution
- Impaired fusion leads to accumulation of autophagic intermediates
Pathogenic Mutations and Autophagy
LRRK2 pathogenic mutations disrupt autophagy at multiple levels:
| Mutation Type | Autophagy Effect |
|-------------|-----------------|
| G2019S (kinase) | Hyperactive kinase, hyperphosphorylation of Rab proteins, impaired membrane trafficking |
| R1441C/G (ROC) | Constitutive GTP-bound state, chronic activation, disrupted Rab function |
| I2020T (COR) | Impaired kinase-ROC communication, altered substrate access |
Therapeutic Targeting
Autophagy modulation is a key therapeutic strategy for LRRK2-associated PD:
- LRRK2 inhibitors: Reduce Rab hyperphosphorylation, restore normal trafficking
- Autophagy enhancers: mTOR inhibitors, autophagy-inducing compounds
- Lysosomal modulators: TFEB activators, cathepsin enhancers
Mitochondrial Dysfunction
LRRK2 Localization to Mitochondria
LRRK2 is localized to mitochondria in neurons and other cell types, where it can influence mitochondrial function through multiple mechanisms.
Mitochondrial Dynamics
LRRK2 regulates mitochondrial dynamics through Rab phosphorylation:
- Rab10 phosphorylation affects mitochondrial fission
- LRRK2 modulates the distribution of mitochondria in neuronal processes
- Pathogenic LRRK2 disrupts the balance between fusion and fission
Mitophagy
LRRK2 is involved in the selective autophagy of damaged mitochondria (mitophagy):
- LRRK2 kinase activity can modulate Parkin recruitment
- Rab proteins regulate mitophagosome formation
- LRRK2 mutations impair the clearance of damaged mitochondria
Oxidative Stress
LRRK2 dysfunction contributes to oxidative stress in PD:
- Mitochondrial dysfunction increases reactive oxygen species (ROS) production
- LRRK2 can modulate antioxidant responses
- Oxidative stress further damages mitochondria in a feed-forward loop
LRRK2-Mitochondrial Interactions in Dopaminergic Neurons
Dopaminergic neurons are particularly vulnerable to mitochondrial dysfunction:
- High metabolic demands require robust mitochondrial function
- Dopamine metabolism generates ROS as a byproduct
- LRRK2 mutations exacerbate the inherent vulnerability of these neurons
Therapeutic Implications
Mitochondrial protection is a key therapeutic goal:
- LRRK2 inhibitors: Reduce kinase hyperactivity, restore normal mitochondrial function
- Mitochondrial antioxidants: CoQ10, MitoQ, and other compounds
- Mitophagy enhancers: Promote clearance of damaged mitochondria
LRRK2 Signaling Cascade
The following diagram illustrates the major signaling pathways regulated by LRRK2 in Parkinson's disease:
Mermaid diagram (expand to render)
Key Signaling Nodes
LRRK2 kinase activation → Hyperphosphorylation of Rab substrates
Rab dysfunction → Impaired membrane trafficking
Trafficking impairment → Autophagy/lysosomal dysfunction
Clearance failure → Protein aggregate accumulation
Energy crisis → Mitochondrial dysfunction
Synaptic failure → Neuronal dysfunction and deathTherapeutic Target Points
The signaling cascade offers multiple intervention points:
- Primary target: LRRK2 kinase activity (direct inhibition)
- Downstream targets: Rab function, autophagy flux, lysosomal function
- Alternative approaches: Mitochondrial protection, synaptic support
LRRK2 Clinical Development Update (2025-2026)
BIIB122 Phase 2 Trial Results
The BIIB122 Phase 2 clinical trial for early Parkinson's disease reported results in 2025[@biib122trial2025]:
- Trial enrolled patients with LRRK2 G2019S mutations and sporadic PD
- Primary endpoint: change from baseline in MDS-UPDRS Part III score
- Results showed dose-dependent Rab10 phosphorylation inhibition in peripheral blood mononuclear cells
- Biomarker evidence of target engagement at selected doses
LRRK2 as a Disease-Modifying Target
A comprehensive 2026 review positioned LRRK2 as a leading disease-modifying target in PD[@lrrk2026]:
- LRRK2 kinase hyperactivity drives multiple pathogenic pathways relevant to both familial and sporadic PD
- G2019S mutation carriers show elevated phospho-Rab10 in blood and CSF, providing pharmacodynamic biomarker
- LRRK2 inhibitors achieve CNS penetration and reduce substrate phosphorylation in human neurons
Lysosomal Damage Sensing
A landmark 2025 study revealed that LRRK2 functions as a lysosomal damage sensor[@lrrk2025]:
- LRRK2 is recruited to lysosomes upon membrane damage
- G2019S mutation causes constitutive recruitment to damaged lysosomes
- Rab phosphorylation at lysosomal membranes disrupts autophagosome-lysosome fusion
LRRK2 Oligomers in Pathogenesis
Recent structural studies have identified LRRK2 oligomers as a pathogenic species[@lrrk2026b]:
- LRRK2 forms oligomers in patient brain tissue and iPSC-derived neurons
- Oligomeric LRRK2 can spread between cells
- Oligomer-targeting antibodies reduce toxicity in cellular models
LRRK2 and Alpha-Synuclein Exosomal Release
Research confirms that LRRK2 G2019S enhances exosomal release of [alpha-synuclein](/proteins/alpha-synuclein)[@sekiya2025]:
- LRRK2 phosphorylates Rab8a and Rab10, regulating exosome biogenesis and release
- G2019S mutation increases exosomal alpha-synuclein in patient-derived neurons
- LRRK2 inhibitors reduce exosomal alpha-synuclein release
Therapeutic Pipeline
The LRRK2 inhibitor pipeline has expanded significantly[@lrrk2025b]:
| Compound | Company | Development Stage | Notes |
|----------|---------|-------------------|-------|
| BIIB122 | Biogen/Denali | Phase 2 completed | Oral, once-daily dosing |
| DNL312 | Denali | Phase 1 | Improved CNS penetration |
| Multiple candidates | Various | Preclinical | Next-gen compounds |
Rab Phosphorylation in Human Neurons
Detailed studies in human neurons have clarified LRRK2 substrate specificity[@lrrk2025c]:
- Comprehensive mapping of LRRK2-phosphorylated Rab proteins in human neurons
- Rab8a, Rab10, and Rab12 are primary substrates in human neurons
- Rab12 phosphorylation emerges as a novel biomarker candidate
Summary
The LRRK2 pathway represents a central node in Parkinson's disease pathogenesis, linking genetic risk to molecular mechanisms that affect neuronal function across multiple domains. The identification of pathogenic mutations and the elucidation of downstream signaling pathways, particularly Rab phosphorylation, have provided actionable targets for therapeutic intervention. LRRK2 inhibitors in clinical development offer the prospect of precision medicine approaches for the subset of PD patients carrying pathogenic variants, while insights into LRRK2 biology may also benefit broader PD populations.
See Also
- [LRRK2](/genes/lrrk2)
- [LRRK2 Protein](/proteins/lrrk2-protein)
- [LRRK2 Inhibitors](/therapeutics/lrrk2-inhibitors)
- [GBA](/genes/gba)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
- [Autophagy Pathway](/mechanisms/autophagy)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
External Links
- Allen Human Brain Atlas: [LRRK2 expression](https://human.brain-map.org/microarray/search/show?search_term=LRRK2) — Search for LRRK2 gene expression across brain regions
- Allen Cell Type Atlas: [Cell type-specific RNA-seq](https://brain-map.org/atlases-and-data/rnaseq) — View LRRK2 expression across neuronal and glial cell types
- BrainSpan: [Developmental transcriptome](https://www.brainspan.org/rnaseq/search/index.html?search_term=LRRK2) — LRRK2 expression across brain development
- Allen Mouse Brain Atlas: [Lrrk2 expression in mouse](https://mouse.brain-map.org/search/index?query=Lrrk2) — Explore in mouse models of PD
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Zimprich et al., LRRK2 mutations causing familial Parkinson's disease (2004) (2004)](https://doi.org/10.1016/j.neuron.2004.11.005))
[Paisan-Ruiz et al., LRRK2 gene mutations in PD (2004) (2004)](https://doi.org/10.1016/j.neuron.2004.11.004))
[Steger et al., LRRK2 phosphorylates Rab GTPases (2016) (2016)](https://doi.org/10.1016/j.cell.2016.09.021))
[Cook et al., LRRK2 in microglia and neuroinflammation (2017) (2017)](https://doi.org/10.1016/j.tins.2017.07.002))
[Moehle et al., LRRK2 inhibition as therapeutic strategy (2019) (2019)](https://doi.org/10.1002/mds.27570))
[Tolosa et al., LRRK2 in 2024: Genetics, biology and therapy (2024) (2024)](https://doi.org/10.1002/mds.29763))
[Jensen et al., LRRK2 biomarkers for clinical trials (2023) (2023)](https://doi.org/10.1002/mds.29368))
[Blandini et al., LRRK2 function in dopamine neurons (2019) (2019)](https://doi.org/10.1002/mds.27773))
[Schapansky et al., LRRK2 in dopaminergic neuron biology (2015) (2015)](https://doi.org/10.1016/j.neurobiologyofaging.2015.01.017))
[Deng et al., LRRK2 mouse models (2019) (2019)](https://doi.org/10.1002/mds.27839))
[Volta et al., LRRK2 animal models review (2017) (2017)](https://doi.org/10.1002/mds.26881))
[Alegre-Abarrategui et al., LRRK2 in Drosophila (2019) (2019)](https://doi.org/10.1002/mds.27643))
[Biskup et al., LRRK2 kinase domain structure (2006) (2006)](https://doi.org/10.1016/j.neurobiolaging.2006.10.004))
[Jorgensen et al., LRRK2 GTPase domain (2015) (2015)](https://doi.org/10.1093/brain/awv137))
[Mills et al., LRRK2 inhibitors clinical development (2022) (2022)](https://doi.org/10.1002/mds.29065))
[Kumar et al., LRRK2 Rab phosphorylation (2020) (2020)](https://doi.org/10.1016/j.tins.2020.02.004))
[Wallings et al., LRRK2 and autophagy (2019) (2019)](https://doi.org/10.1016/j.neurobiologyofaging.2019.06.004))
[Daher et al., LRRK2 mitochondrial dysfunction (2015) (2015)](https://doi.org/10.1016/j.neurobiolaging.2015.03.012))
[Ferreira et al., LRRK2 iPSC models (2017) (2017)](https://doi.org/10.1002/mds.26860))
[Tolosa et al., LRRK2 clinical trials update (2021) (2021)](https://doi.org/10.1002/mds.28464))
[Steger et al., LRRK2 phospho-Rab10 biomarker (2017) (2017)](https://doi.org/10.1002/mds.26965))
[Unknown, Pupyshev, LRRK2 inhibitors (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33594662/))
[Blaehr L et al., GBA1 and LRRK2 converge on lysosomal function (2024)](https://pubmed.ncbi.nlm.nih.gov/32901234/))
[Jensen PH et al., LRRK2 and GBA cooperation in Parkinson's disease (2024)](https://doi.org/10.1038/s41593-024-01567-w))
[Kim CY et al., GBA mutations modify LRRK2-associated Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37094321/))